A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Too Much Chicken? New Research Finds Link to Increased Risk of Early DeathA recent study published in the journal Nutrients ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that ...

Researchers chose to investigate semaglutide as a potential treatment because this class of drug has previously been shown to reduce fat and liver scarring for people with MASH. Between 2021 and ...